President Trump's plan to levy tariffs on imported pharmaceuticals is drawing criticism from all sides of the political spectrum.

"Domestic manufacturing matters, but doing it by taxing patients through tariffs is the wrong move," Natasha Murphy, MSPH, director of health policy at the Center for American Progress, a left-leaning Washington think tank, said in an email to MedPage Today . "These costs won't be eaten by drugmakers and instead will be passed on to families in the form of higher premiums and tighter formularies ... This is Trump's tariff-first playbook at work, and it puts affordability and access at risk."

"All tariffs are a bad idea," Michael Baker, MS, director of healthcare policy at the American Action Forum, a right-leaning Washington think tank, said in a phone inter

See Full Page